A Case of Pyrazinamide Induced Fulminant Hepatic Failure / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
; : 435-439, 2007.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-59557
Responsible library:
WPRO
ABSTRACT
Standard antituberculous therapy, including isoniazid (INH), rifampin, ethambutol, and pyrazinamide (PZA), is widely used to treat active tuberculosis. The most important side effect is hepatotoxicity. In a standard four-drug regimen, PZA was the most common cause of drug-induced hepatitis and was dose-related. The incidence of drug-induced hepatitis is high at doses of 40~70 mg/kg per day but has fallen significantly since the recommended dose was reduced. Liver toxicity induced by PZA is rare at doses of 25 mg/kg per day or less. PZA-induced fulminant hepatic failure is also rare but fatal. We report a case of fulminant hepatic failure caused by a re-challenge of PZA.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
/
Neglected Diseases
Health problem:
Target 3.3: End transmission of communicable diseases
/
Neglected Diseases
/
Tuberculosis
Database:
WPRIM (Western Pacific)
Main subject:
Pyrazinamide
/
Rifampin
/
Tuberculosis
/
Incidence
/
Liver Failure, Acute
/
Ethambutol
/
Chemical and Drug Induced Liver Injury
/
Isoniazid
/
Liver
Type of study:
Incidence study
/
Prognostic study
Language:
Korean
Journal:
Tuberculosis and Respiratory Diseases
Year:
2007
Document type:
Article